Search

Your search keyword '"Azam, Tariq U."' showing total 46 results

Search Constraints

Start Over You searched for: Author "Azam, Tariq U." Remove constraint Author: "Azam, Tariq U." Publication Year Range Last 10 years Remove constraint Publication Year Range: Last 10 years
46 results on '"Azam, Tariq U."'

Search Results

1. Intubation Decision Based on Illness Severity and Mortality in COVID-19: An International Study*

2. Biomarker Trends, Incidence, and Outcomes of Immune Checkpoint Inhibitor–Induced Myocarditis

4. Kidney Recovery and Death in Critically Ill Patients With COVID-19–Associated Acute Kidney Injury Treated With Dialysis: The STOP-COVID Cohort Study

5. Differences in Inflammation, Treatment, and Outcomes Between Black and Non-Black Patients Hospitalized for COVID-19: A Prospective Cohort Study

6. In-hospital cardiac arrest in critically ill patients with covid-19 : multicenter cohort study

7. Modulation of the Association Between Age and Death by Risk Factor Burden in Critically Ill Patients With COVID-19

8. Biomarkers of chronic inflammation and cognitive decline: A prospective observational study

9. Machine Learning Prediction of Death in Critically Ill Patients With Coronavirus Disease 2019

11. Abstract 15365: Natural History of Immune Checkpoint Inhibitor Associated Myocarditis With Preserved Ejection Fraction

12. Abstract 14843: Electrocardiographic Manifestations of Immune Checkpoint Inhibitor Associated Myocarditis

13. SuPAR, biomarkers of inflammation, and severe outcomes in patients hospitalized for COVID‐19: The International Study of Inflammation in COVID‐19.

14. Soluble Urokinase Plasminogen Activator Receptor and Venous Thromboembolism in COVID‐19

15. Permissive Cardiotoxicity

16. Inflammation, Hyperglycemia, and Adverse Outcomes in Individuals With Diabetes Mellitus Hospitalized for COVID-19

17. Association of early electrical changes with cardiovascular outcomes in immune checkpoint inhibitor myocarditis

18. Outcomes of critically ill solid organ transplant patients with COVID-19 in the United States

20. Inflammation, Hyperglycemia, and Adverse Outcomes in Individuals With Diabetes Mellitus Hospitalized for COVID-19

21. Association of Surge Conditions with Mortality Among Critically Ill Patients with COVID-19

22. Electrocardiographic Manifestations of Immune Checkpoint Inhibitor Myocarditis

23. Performance of crisis standards of care guidelines in a cohort of critically ill COVID-19 patients in the United States

24. Performance of crisis standards of care guidelines in a cohort of critically ill COVID-19 patients in the United States

25. Identification of Distinct Clinical Subphenotypes in Critically Ill Patients With COVID-19

26. Hospital-Level Variation in Death for Critically Ill Patients with COVID-19

27. Soluble Urokinase Plasminogen Activator Receptor and Venous Thromboembolism in COVID-19.

29. Thrombosis, Bleeding, and the Observational Effect of Early Therapeutic Anticoagulation on Survival in Critically Ill Patients With COVID-19

30. CARDIOVASCULAR DISEASE AND OUTCOMES IN CRITICALLY ILL PATIENTS WITH COVID-19: A STOP-COVID ANCILLARY

31. Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Outcomes in Patients Hospitalized for COVID-19

32. Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19

33. Characteristics and Outcomes of Individuals With Pre-existing Kidney Disease and COVID-19 Admitted to Intensive Care Units in the United States

34. Soluble Urokinase Receptor (SuPAR) in COVID-19-Related AKI

35. Inflammation, Hyperglycemia, and Adverse Outcomes in Individuals With Diabetes Mellitus Hospitalized for COVID-19.

36. In-hospital cardiac arrest in critically ill patients with covid-19: multicenter cohort study

37. ADAM10 and ADAM17 cleave PD-L1 to mediate PD-(L)1 inhibitor resistance

38. Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Outcomes in Patients Hospitalized for COVID-19.

39. Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US

40. Abstract A210: Tumor-associated ADAM10 and ADAM17 produce soluble PD-L1 (sPD-L1, sB7-H1) and affect downstream tumor immunity – A resistance mechanism to PD-1 checkpoint blockade in melanoma

41. Characterization of Comorbidities Limiting the Recruitment of Patients in Early Phase Clinical Trials

42. Characterization of Comorbidities Limiting the Recruitment of Patients in Early Phase Clinical Trials.

43. Relationship Between Preexisting Cardiovascular Disease and Death and Cardiovascular Outcomes in Critically Ill Patients With COVID-19.

44. Gender Parity in Medical School Does Not Equal Gender Parity in Medical School Leadership.

45. Biomarkers of chronic inflammation and cognitive decline: A prospective observational study.

46. Soluble Urokinase Receptor (SuPAR) in COVID-19-Related AKI.

Catalog

Books, media, physical & digital resources